TLX101-Tx plus standard care versus standard care alone for recurrent glioblastoma

A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients With Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX BrIGHT [IPAX-3])

This test checks whether adding TLX101-Tx, a tumor-targeted radiopharmaceutical given with lomustine, helps adults with first-recurrence glioblastoma control their tumor or live longer compared with lomustine alone.

Quick facts

• Phase: Phase 3
• Study type: Interventional
• Enrollment: 50 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited (Industry-sponsored)
• Drugs / interventions: bevacizumab, radiation
• Locations: 4 sites (Gold Coast, Queensland and 3 other locations)
• Trial ID: NCT07100730 on ClinicalTrials.gov

What this trial studies

TLX101-Tx is an investigational radiopharmaceutical designed to deliver targeted radiation to glioblastoma cells and is administered in combination with lomustine. The global Phase 3 program has two parts: Part 1 determines safety and radiation dosing, and Part 2 randomly compares the combination against lomustine alone in adults with first recurrence. Eligible patients must have IDH‑wildtype glioblastoma with radiographic recurrence at least three months after prior radiotherapy and increased [18F]FET PET uptake at the tumor site. Key outcomes include safety, radiation exposure, tumor control measures, and survival.

Who should consider this trial

Good fit: Adults with IDH‑wildtype glioblastoma at their first radiographic recurrence, at least three months after prior radiotherapy, and with increased [18F]FET PET uptake are the intended candidates.

Not a fit: Patients with non‑GBM diagnoses, IDH‑mutant tumors, later recurrences, absent or low [18F]FET PET uptake, or poor performance status are unlikely to qualify or benefit.

Why it matters

Potential benefit: If successful, the combination could improve tumor control and extend survival by delivering radiation directly to tumor cells while limiting exposure to normal brain.

How similar studies have performed: Early-phase studies of targeted radiopharmaceuticals in brain tumors have shown safety and preliminary activity, but randomized phase 3 proof of benefit in recurrent GBM is not yet established.

Eligibility criteria

Inclusion Criteria:

1. Previously confirmed neuropathological diagnosis of glioblastoma, IDH-wildtype according to the WHO 2021 classification.
2. Radiographic evidence of first recurrence or progressive glioblastoma according to RANO 2.0 criteria after first-line treatment with biopsy or maximal safe resection and standard radiotherapy or chemoradiotherapy having occurred at least 3 months after the end of prior radiotherapy. Prior first-line therapy may include a combination of:

   1. Any systemic antineoplastic treatment other than nitroureas
   2. Tumor-treating fields
   3. Conventionally fractionated or abbreviated (minimum 15 fractions) radiotherapy
3. Increased \[18F\]\]FET PET tracer uptake inside or in the vicinity of tumor. Specifically, amino acid-based molecular imaging using \[18F\]FET PET will be evaluated following co-registration with MRI. The allocated physician/reader will assess whether the observed pathologically increased amino acid uptake is located within the tumor or in the vicinity. This determination will serve as a guidance to confirm whether the uptake is tumor-associated. The uptake must be clearly discernible from background activity and measurable per PET RANO 1.0 criteria, as determined by central review.
4. Tumor debulking for recurrent, progressive disease is allowed. The patient must have post-surgical (4-6 weeks) radiographic evidence for residual tumor according to RANO 2.0 with increased \[18F\] FET PET uptake and measurable disease according to PET RANO 1.0.
5. 18 years or older
6. Have the capacity to understand the study and be willing to comply with all protocol requirements.
7. Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2 or KPS≥70
8. Patients on stable, not increasing dose of steroids in the previous 7 days can be included in the study
9. Adequate hematological, liver and renal function at the time of screening.
10. Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose of investigational drug product; must not be breast-feeding; and must agree to use a highly effective method of contraception during treatment and for 6 months following last dose of investigational product.
11. Male patients must agree to use condoms during sex during the treatment period and for 3 months after the last dose of the investigational drug product and must not make semen donations during treatment and for 6 months following last dose of investigational drug product. For male patients with female partners of childbearing potential, females must agree to use a highly effective method of contraception during the treatment period and for 6 months following last dose of investigational drug product.

Exclusion Criteria:

1. Prior course with external beam radiation to the brain in the past 3 months. Prior treatment with brachytherapy in the brain.
2. Treatment with bevacizumab within the prior 6 weeks.
3. Known contraindication to imaging tracer or any product of contrast media and MRI contraindications including implanted medical devices. Unable to lie still for at least 20 min or the duration of the MRI and PET imaging or the need for general anesthesia as part of the imaging procedure.
4. History or evidence of delayed-type hypersensitivity-dependent chronic infection (ie, tuberculosis, systemic fungal or parasitic infection).
5. Radiographic progression based on RANO 2.0 associated with clinical deterioration and life expectancy less than 3 months.
6. Hemostaseologic conditions, precluding catheterization or invasive procedures.
7. Clinically significant illness or clinically relevant trauma within 2 weeks before the administration of the investigational product.
8. Known liver or kidney disease, such as hepatitis, cirrhosis, renal failure.
9. Severe chronic or active infections (including active tuberculosis, hepatitis B virus, or hepatitis C virus infection) requiring systemic therapy.
10. Ongoing toxicity \> Grade 2 NCI-CTCAE (version 5.0) from previous standard or investigational therapies.
11. Administration of another investigational product within 90 days prior to screening.
12. Expected non-compliance with longer-term admission at isolated nuclear medicine ward per regional regulations.
13. Inability to complete the needed investigational and standard imaging examinations due to any reason (ie, severe claustrophobia, inability to lie still for the entire imaging time).
14. Patients with known phenylketonuria.
15. Presence of any other condition that may increase the risk associated with study participation or interfere with the interpretation of study results, and, in the opinion of the study investigator, would make the patient inappropriate for entry into the study.

Where this trial is running

Gold Coast, Queensland and 3 other locations

• Gold Coast University Hospital — Gold Coast, Queensland, Australia (Recruiting)
• Austin Health — Melbourne, Australia (Recruiting)
• Johannes Kepler University — Linz, Austria (Recruiting)
• UMC Utrecht — Utrecht, Netherlands (Recruiting)

Study contacts

• Study coordinator: Clinical Project Manager

Conditions Neoplastic Disease; Glioblastoma; Glioblastoma Multiform; Glioblastoma Multiforme, Adult; Glioblastoma Multiforme WHO Grade IV; Lomustine; Radiation Therapy; Radiopharmaceuticals